AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
Healthcare
$47.40 -1.88%
-$1.07 today
- Market cap
- $1.41B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
52W Low $11.40High $72.36
Volume 0.51M
Average 0.76M
Balance Sheet
Inspect the capital base behind the business.
Assets
$364.39M
FY 2025 · Annual
-24.7% YoYLiabilities
$327.19M
FY 2025 · Annual
-20.8% YoYEquity
$37.21M
FY 2025 · Annual
-47.5% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 495.73M | 71.31M | 35.97M | 123.08M | 238.2M |
| Short-term Investments | 52.37M | 369.93M | 354.94M | 262.29M | 73.44M |
| Net Receivables | 876K | 1.42M | 6.85M | 40.77M | 33.85M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.55M | 9.08M | 5.74M | 4.76M |
| Total Current Assets | 553.88M | 447.21M | 406.84M | 431.88M | 350.25M |
| Property, Plant & Equipment (Net) | 21.84M | 19.99M | 18.27M | 16.23M | 13.89M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 67.1M | 142.94M | 27.03M | 35.47M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 256K | 256K | 256K | 256K | 256K |
| Total Non-current Assets | 89.19M | 163.18M | 45.55M | 51.96M | 14.15M |
| Total Assets | 643.07M | 610.38M | 452.39M | 483.83M | 364.4M |
| Account Payables | 1.74M | 2.78M | 4.7M | 4M | 3.87M |
| Short-term Debt | 0 | 0 | 0 | 1.93M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.18M | 5.38M | 23.77M | 31.05M | 11.09M |
| Total Current Liabilities | 16.1M | 26.05M | 37.44M | 45.43M | 38.63M |
| Long-term Debt | 0 | 0 | 0 | 353.43M | 12.03M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 251.09M | 304.41M | 310.81M | 0 | 276.53M |
| Total Non-current Liabilities | 270.54M | 322.23M | 326.84M | 367.54M | 288.56M |
| Total Liabilities | 286.64M | 348.28M | 364.29M | 412.97M | 327.19M |
| Common Stock | 28K | 29K | 27K | 30K | 28K |
| Retained Earnings | (321.75M) | (450.48M) | (614.1M) | (759.33M) | (772.56M) |
| Accumulated OCI | (422K) | (5.25M) | (797K) | 305K | (24K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 356.43M | 262.1M | 88.1M | 70.87M | 37.21M |
| Total Debt | 20.96M | 19.45M | 17.81M | 369.46M | 14.11M |
| Net Debt | (474.77M) | (51.86M) | (18.15M) | 246.38M | (224.08M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $248.5M |
| Short-term Investments | $38.0M |
| Receivables | $25.7M |
| Other Current | $3.9M |
| Total Current Assets | $316.1M |
| PP&E (Net) | $13.3M |
| Other Non-current | $256.0K |
| Total Non-current Assets | $13.6M |
| Total Assets | $329.7M |
Analysis
Selected assets total $329.7M for Latest. The largest visible component is Cash & Equivalents at $248.5M, about 75.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 10-KT | 10-KT filing | Sep 21, 2026 | |
| 8-K | Current report | Sep 21, 2026 |
How much cash does ANAB have?
AnaptysBio, Inc. (ANAB) reported $238.20M in cash and equivalents in fiscal 2025.
How much debt does ANAB carry?
AnaptysBio, Inc. (ANAB) reported $14.11M of total debt, with net debt of -$224.08M.
Continue the stock analysis
Jump to another research area for this company.